B³ Pharma is a late-stage biopharma company advancing its Angiopep-drug conjugate platform to deliver therapies across the blood-brain barrier. With a solid clinical pipeline and upcoming Phase III trials, we are committed to transforming treatment for patients with brain metastases and other CNS disorders.
We are advancing a versatile Angiopep platform with applications across oncology and CNS. Our approach is adaptable to multiple drug modalities, from small molecules to biologics.
B³ Pharma is led by an experienced team of biotech pioneers, driving innovation in oncology and central nervous system diseases through its proprietary Angiopep technology.
Whether you are an investor, researcher, or potential partner, we invite you to connect with our team. Together, we can accelerate the development of life-changing therapies and bring innovative solutions to patients in need.
